Collaboration Details

Title of Collaborative Activity:

TB Trials Consortium Study 26/ACTG 5259: A Study of the Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for Three Months Versus Daily Isoniazid for Nine Months for the Treatment of Latent Tuberculosis Infection

Description of Collaborative Activity:

Phase III clinical trial to compare the effectiveness of a three-month (12-dose) regimen of weekly rifapentine and isoniazid (3RPT/INH) and a nine-month (270-dose) regimen of daily isoniazid (9INH). Trial conducted among high-risk tuberculin skin-test reactors, including children and HIV-infected persons, who require treatment of latent infection to prevent tuberculosis. The 3RPT/INH regimen will be given under direct observation and the 9INH regimen will be primarily self-administered.

Type of Collaborative Activity:

Select Type of Collaborative Activity

Year the Collaborative Activity Originated:

2008

NIH Participating Institutes/Centers/Office of the Director:

NIAID

HHS Agency Collaborators on this Activity:

CDC